We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-19.24%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$384M
AUM Growth
-$13.9M
Cap. Flow
+$77.9M
Cap. Flow %
20.3%
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4

Top Buys

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$24.9M
2
IBB icon
iShares Biotechnology ETF
IBB
+$8.02M
3
FATE icon
Fate Therapeutics
FATE
+$4.99M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$4.59M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$4.37M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$11.1M
2
OTIC
Otonomy, Inc.
OTIC
+$1.49M
3
HOOK
HOOKIPA Pharma
HOOK
+$747K
4
PRQR icon
ProQR Therapeutics
PRQR
+$685K
5
XENE icon
Xenon Pharmaceuticals
XENE
+$674K

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
76
Sutro Biopharma
STRO
$421M
$696K 0.18%
8,470
+3,970
+88% +$378K
PHVS icon
77
Pharvaris
PHVS
$2.44B
$628K 0.16%
34,615
-2,105
-6% -$37.1K
LVTX
78
DELISTED
LAVA Therapeutics
LVTX
$613K 0.16%
139,332
– –
HARP
79
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$523K 0.14%
10,516
– –
PHAS
80
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$500K 0.13%
378,611
– –
INGN icon
81
Inogen
INGN
$164M
$486K 0.13%
15,000
– –
SCYX icon
82
SCYNEXIS
SCYX
$52M
$474K 0.12%
15,155
– –
MASI
83
DELISTED
Masimo
MASI
$437K 0.11%
3,000
– –
CGEN icon
84
Compugen
CGEN
$228M
$419K 0.11%
130,202
-71,300
-35% -$241K
MDGL icon
85
Madrigal Pharmaceuticals
MDGL
$11.8B
$304K 0.08%
3,100
-2,500
-45% -$211K
CMPX icon
86
Compass Therapeutics
CMPX
$387M
$269K 0.07%
196,091
– –
ASLN
87
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$219K 0.06%
6,093
-12,220
-67% -$454K
LCTX icon
88
Lineage Cell Therapeutics
LCTX
$278M
$216K 0.06%
140,000
+60,000
+75% +$93.1K
LRMR icon
89
Larimar Therapeutics
LRMR
$432M
$202K 0.05%
49,996
-20,181
-29% -$132K
SRGA
90
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$176K 0.05%
19,324
– –
INFI
91
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$137K 0.04%
120,097
-116,063
-49% -$139K
ANNX icon
92
Annexon
ANNX
$886M
$84K 0.02%
30,796
– –
BOLT icon
93
Bolt Biotherapeutics
BOLT
$7.78M
– –
-5,000
Closed -$490K
HOOK
94
DELISTED
HOOKIPA Pharma
HOOK
– –
-32,044
Closed -$747K
PRQR icon
95
ProQR Therapeutics
PRQR
$265M
– –
-85,476
Closed -$685K
ARNA
96
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-119,615
Closed -$11.1M
1 2 3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return
BCM
Beck Capital Management Austin, Texas $437M AUM 59.35% 1-Year Est. Return

DAFNA Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, DAFNA Capital Management held 98 positions worth $384M, down 3.5% from $398M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

DAFNA Capital Management deployed $77.9M of net new capital in Q1 2022, opening 11 new positions and adding to 36 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Otonomy, Inc., an estimated $1.49M trimmed.

  • DAFNA Capital Management's largest Q1 2022 buy was State Street SPDR S&P Biotech ETF: 269,500 shares worth $24.2M.
  • DAFNA Capital Management added most to iShares Biotechnology ETF in Q1 2022, an estimated $8.02M increase.
  • DAFNA Capital Management's biggest Q1 2022 reduction was Otonomy, Inc., cutting an estimated $1.49M.
  • DAFNA Capital Management fully exited Arena Pharmaceuticals Inc in Q1 2022, selling an estimated $11.1M.
  • DAFNA Capital Management's ten largest holdings make up 47% of its $384M portfolio in Q1 2022.
  • DAFNA Capital Management opened 11 new positions and closed 4 in Q1 2022.
  • DAFNA Capital Management's portfolio value fell 3.5% quarter-over-quarter to $384M.

Based on DAFNA Capital Management's 13F filing for Q1 2022, filed 16 May 2022.